Personalis Inc
PSNL
查看详细走势图
8.055USD
+0.640+8.63%
收盘 02/06, 16:00（美东）报价延迟15分钟
714.84M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+8.63%
5天
-14.03%
1月
-13.85%
6月
+77.23%
今年开始到现在
+1.19%
1年
+63.72%
查看详细走势图
TradingKey Personalis Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Personalis Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名102/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价11.00。中期看，股价处于平稳状态。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Personalis Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Personalis Inc亮点
亮点风险
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
业绩高增长
公司营业收入稳步增长，连续3年增长30.08%
业绩增长期
公司处于发展阶段，最新年度总收入84.61M美元
估值低估
公司最新PE估值-9.62，处于3年历史低位
机构加仓
最新机构持股60.23M股，环比增加11.24%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值12.72K
分析师目标
根据
7
位分析师
买入
评级
11.000
目标均价
+32.37%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Personalis Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Personalis Inc简介
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
公司代码PSNL
公司Personalis Inc
CEOHall (Christopher M)
网址https://www.personalis.com/
相关品种
